Early IVIG Reduces Infections in Transplant Patients

A clinical trial at the Universidad Autónoma de Madrid (UAM) suggests that early administration of intravenous immune globulin (IVIG) could decrease the occurrence of new infections in transplanted individuals who present with hypogammaglobulinemia. The study focused on patients who had suffered a severe infection after transplantation and showed a concentration of IgG below 600 mg/dL.

In the trial, participants were randomly assigned to two groups. All received the standard antimicrobial regimen, but one of the groups was also treated with five doses of IVIG administered over approximately three months. At the end of the observation period, the researchers analyzed and compared the incidence of new infections between both groups and found complementing conventional treatment with IVIG can significantly decrease the likelihood of suffering new infections. This intervention was also associated with an increase in the concentrations of different antibodies directed against various microorganisms.

According to the researchers, these results support a possible therapeutic strategy: administering IVIG to transplanted patients who develop a severe infection and present with hypogammaglobulinemia. Because this is a PhaseII trial, the researchers say it will be necessary to confirm these findings in studies with a larger number of participants before considering their widespread incorporation into clinical practice.